These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32796688)

  • 1. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN; Yerra VG; Liu Y; Advani SL; Klein T; Advani A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together.
    Wang X; Ding Z; Yang F; Dai Y; Chen P; Theus S; Singh S; Budhiraja M; Mehta JL
    Clin Sci (Lond); 2016 Aug; 130(15):1353-62. PubMed ID: 27129181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
    Adhikari J; Hirai T; Kawakita E; Iwai K; Koya D; Kanasaki K
    J Diabetes Investig; 2023 Jul; 14(7):844-855. PubMed ID: 37092329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular effects of linagliptin in non-obese diabetic mice are glucose-independent and involve positive modulation of the endothelial nitric oxide synthase (eNOS)/caveolin-1 (CAV-1) pathway.
    Vellecco V; Mitidieri E; Gargiulo A; Brancaleone V; Matassa D; Klein T; Esposito F; Cirino G; Bucci M
    Diabetes Obes Metab; 2016 Dec; 18(12):1236-1243. PubMed ID: 27460695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
    Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
    PLoS One; 2015; 10(11):e0143941. PubMed ID: 26618855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.
    Wang SC; Wang XY; Liu CT; Chou RH; Chen ZB; Huang PH; Lin SJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
    Ide M; Sonoda N; Inoue T; Kimura S; Minami Y; Makimura H; Hayashida E; Hyodo F; Yamato M; Takayanagi R; Inoguchi T
    PLoS One; 2020; 15(2):e0228750. PubMed ID: 32032367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
    Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
    Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
    Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.
    Hasegawa Y; Hayashi K; Takemoto Y; Cheng C; Takane K; Lin B; Komohara Y; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2017 Dec; 16(1):154. PubMed ID: 29195509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.
    Al-Awar A; Almási N; Szabó R; Takacs I; Murlasits Z; Szűcs G; Török S; Pósa A; Varga C; Kupai K
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway.
    Suda M; Shimizu I; Yoshida Y; Hayashi Y; Ikegami R; Katsuumi G; Wakasugi T; Yoshida Y; Okuda S; Soga T; Minamino T
    PLoS One; 2017; 12(8):e0182422. PubMed ID: 28771625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
    Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
    Nishida S; Matsumura T; Senokuchi T; Murakami-Nishida S; Ishii N; Morita Y; Yagi Y; Motoshima H; Kondo T; Araki E
    Biochem Biophys Res Commun; 2020 Mar; 524(1):8-15. PubMed ID: 31964532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.